Report Sparks Debate Over Alleged Use Of CME To Promote Unapproved Drugs

A recently released white paper raised concerns over the pharmaceutical industry's influence in continuing medical education courses, specifically the use of disease-marketing as an alleged “back-door” approach to promoting products not yet approved by FDA. While some industry association and physicians sources echoed the concerns raised in the paper, others vehemently opposed the allegations and stressed the current guidelines put forth the Accreditation Council for Continuing Medical Education (ACCME) adequately mitigate any industry influence in accredited courses. This comes as...